The World Health Organization (WHO) has announced a major breakthrough in global child health by prequalifying the first-ever malaria treatment specifically designed for newborns and young infants. The new formulation, a specialized version of artemether-lumefantrine, targets infants weighing between two and five kilograms — a group previously treated with medicines designed for older children, which carried higher risks of dosing errors and toxicity. This advancement is expected to close a critical treatment gap for the estimated 30 million babies born each year in malaria-endemic regions of Africa, ensuring they receive safe, effective, and age-appropriate care.
In tandem with this medical milestone, the WHO has also prequalified three new rapid diagnostic tests (RDTs) to combat "invisible" malaria parasites. Some strains of the P. falciparum parasite have evolved tolose the specific protein (HRP2) detected by traditional tests, leading to dangerous false negatives and delayed treatment. The new diagnostic tools detect a different protein that the parasite cannot easily shed, providing a reliable alternative for health workers. By integrating these innovative treatments and tests, the WHO aims to revitalize the fight against malaria and protect the world’s most vulnerable populations from a disease that remains a leading cause of childhood mortality.
